Navigation Links
Colorectal cancer patients with gene mutation show better response to cancer agent
Date:10/26/2010

Even though the cancer-treatment agent cetuximab is not considered effective treatment for KRAS (a gene)-mutated metastatic colorectal tumors, new research indicates that patients with colorectal cancer not responding to chemotherapy and a certain variation of this gene who were treated with cetuximab had longer overall and progression-free survival than patients with other KRAS-mutations, according to a study in the October 27 issue of JAMA.

"Recent retrospective correlative analyses of metastatic colorectal cancer trials indicate that patients with KRAS-mutated tumors do not benefit from the anti-epidermal growth factor receptor (EGFR) monoclonal antibodies cetuximab and panitumumab," the authors write. However, they add there are indications that not all KRAS mutations are equal in their biological characteristics, including anecdotal reports indicating that a minority of patients with KRAS-mutated tumors can respond to anti-EGFR therapy.

Wendy De Roock, M.D., of the University of Leuven, Leuven, Belgium, and colleagues conducted a study to examine whether a certain KRAS mutation (p.G13D) may be associated with a better outcome after cetuximab treatment than observed with other KRAS mutations. The study included a pooled data set of 579 patients with chemotherapy-refractory (not responsive to treatment) colorectal cancer treated with cetuximab between 2001 and 2008 and who were included in other clinical trials or received off-study treatment. Various analyses of the data were performed. The main efficacy outcome measure was overall survival; secondary efficacy measures were response rate and progression-free survival.

The researchers found that among patients who received any cetuximab-based treatment (cetuximab monotherapy or cetuximab plus chemotherapy) (n = 571), overall and progression-free survival were significantly longer in patients with p.G13D-mutated tumors (overall survival: n=32; median [midpoint], 7.6 months; progression-free survival, n = 32; median, 4.0 months) than in patients with other KRAS-mutated tumors (overall survival: median, 5.7 months; progression-free survival: median, 1.9 months).

"In a large, retrospective pooled exploratory analysis of patients with chemotherapy-refractory colorectal cancer, we show for the first time that there is a positive association between KRAS p.G13D mutations and cetuximab treatment in regard to better overall and progression-free survival," the authors write. They add this effect may not be due to a real reduction in tumor burden but to a delay in progression.

"Prospective randomized trials are needed before conclusions about potential beneficial effects of cetuximab in p.G13D-mutated chemotherapy-refractory metastatic colorectal cancer should be inferred."


'/>"/>

Contact: Sabine Tejpar, M.D., Ph.D.
sabine.tejpar@uzleuven.be
JAMA and Archives Journals
Source:Eurekalert

Related medicine news :

1. Colorectal cancer screening can be expanded by offering it during mammography visits
2. Virtual colonoscopy option could improve colorectal cancer screening rates, patient survey suggests
3. Virtual colonoscopy and teleradiology bring colorectal cancer screening to patients in rural areas
4. Type 2 diabetes and insulin use are associated with colorectal cancer in men
5. Notable racial disparities in diagnosis, treatment and outcomes of colorectal cancer
6. Lack of insurance coverage remains obstacle to wider colorectal cancer screening with CT colonography
7. Colorectal cancer screening in Canada is cost-effective
8. Could Hot Weather Affect Results of a Colorectal Cancer Test?
9. Smoking-related colorectal cancer in older women is associated with molecularly defined DNA changes
10. Smoking-related colorectal cancer in older women is associated with molecularly-defined DNA changes
11. Hydrophobic proteins: Potential biomarkers for colorectal cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)... NY (PRWEB) , ... May 23, 2017 , ... ... in the pharmaceutical and medical device sectors, today announced the winners of its ... • Entrepreneurs) represent the most influential people in the healthcare industry today. , ...
(Date:5/23/2017)... ... May 23, 2017 , ... London, May 23, 2017: Walter Schindler, ... this month as a Guest Speaker and Contributor to a weeklong series of classes, ... Purpose. , Walter Schindler and SAIL Capital have received ...
(Date:5/23/2017)... ... 2017 , ... Diagnotes, an Indianapolis-based digital healthcare communication company, ... secure clinical communication platform. The platform allows clinicians to easily escalate their preferred ... urgency of a situation. , “We know from our daily lives that ...
(Date:5/23/2017)... (PRWEB) , ... May 23, 2017 , ... Therachat ... its new survey in an infographic on the current state of anxiety in support ... familiar with anxiety, was conducted in April 2017 and benchmarked general anxiety levels as ...
(Date:5/22/2017)... (PRWEB) , ... May 22, 2017 , ... Today, Our ... Washington, MO with a public ribbon cutting ceremony. Since opening over a ... an alternative to the emergency room. The new Our Urgent Care walk-in clinic ...
Breaking Medicine News(10 mins):
(Date:5/15/2017)... 2017  Amy Baxter MD, chief executive officer and ... pain relief, was awarded a 2017 Top 40 Healthcare ... recognized at the MM&M Top 40 Healthcare Transformers dinner ... on May 10, 2017. The dinner followed a ... "beyond the pill."  "Innovation goes beyond invention," ...
(Date:5/10/2017)... , May 10, 2017 Global Health Intelligence ... Latin America , published its 2017 ranking of ... is based on extensive data analysis from GHI,s hospitals ... hospitals database for the region. The GHI database covers 86% ... offering more than 130 data points for each institution in ...
(Date:5/9/2017)... , May 9, 2017  Demonstrating its ... board of directors for the Pharmaceutical Research and ... for membership. Biopharmaceutical companies will now have to ... order to be eligible to join PhRMA. ... the board is sending a clear message that ...
Breaking Medicine Technology: